Dual human immunodeficiency virus (HIV) 1 and HIV-2 superinfections are rare but challenging. A HIV-1-infected patient receiving effective antiretroviral therapy was investigated for a severe CD4
+ cell count decline. HIV-2 superinfection was diagnosed and genotypic test revealed mutations conferring resistance to most drug class, limiting options for treatment.
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Human immunodeficiency virus (HIV) 2 was identified in 1986 [1] and accounts for 0.3%-1% of HIV infections worldwide. Outside West Africa, Portugal is one of the countries where HIV-2 infection has a higher incidence [2] . Considered less virulent than HIV-1, HIV-2 usually has lower viremia, higher CD4 + cells counts, and less efficient transmission [3, 4] . Moreover, some antiretrovirals are intrinsically ineffective, such as nonnucleoside reverse-transcriptase inhibitors [5] . We describe a patient receiving antiretroviral therapy (ART) for an HIV-1 infection, with immune recovery and virological suppression for more than a decade, who presented with a severe decline in the CD4 + cell count secondary to HIV-2 superinfection. Figure 1 ). In 2013 (about 11 years after HIV-1 diagnosis) a significant decline in the patient's absolute and relative CD4 + cell counts was noted, down to a nadir of 89/μL (6%). Apart from this CD4 + cell count decline, no other analytical changes were present, and the patient remained asymptomatic (Figure 1 ). Diagnostic workup revealed no autoimmune or hematological cause, and infections such as leishmaniasis and syphilis were excluded. In April 2016, the antibody HIV-1/HIV-2 discrimination test was performed again and was positive for both HIV-1 and HIV-2. The HIV-2 viral load (in-house method) was 5320 copies/μL. The patient then recalled an isolated unprotected sexual intercourse with a casual partner in late 2012 or early 2013 while he was abroad in Brazil (horizontally striped arrow in Figure 1 ). At the time of the likely transmission of HIV-2, the patient was undergoing HIV-1 treatment with emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted atazanavir.
The genotypic test of HIV-2, performed in 2016, revealed a subtype A with the following mutations: I50V, I54M, I82F (protease), N69K, K70T, V111I, Q151M (reverse-transcriptase), T97A and Y143R (integrase). The HIV-2EU 3.0 and Rega 8.0.2 interpretation algorithms revealed consistent susceptibility only to second-generation integrase inhibitors. In addition, HIV-2 was not R5 tropic.
The patient's ART regimen was then optimized to emtricitabine/tenofovir disoproxil fumarate, darunavir with ritonavir boosting (600/100 mg twice daily) and dolutegravir (50 mg twice daily). Over a 1-year period, his HIV-2 viral load became undetectable, and his CD4 + cell count increased to 329/μL (12%) (Figure 1 ). The patient provided informed written consent for the publication of this case report. Ethics committee approval was not required because no personal data are reported.
DISCUSSION
Dual HIV-1 and HIV-2 infections are relatively common in West Africa [6] , though they are scarce elsewhere [7] . In most cases, it is difficult to distinguish coinfection from superinfection because both infections are diagnosed simultaneously [6] . ART selection in these patients is sometimes complicated owing to overlapping resistance [8] . In our clinical case report, we document an HIV-2 superinfection in an ART-adherent patient with HIV-1 viral loads persistently below the level of detection. Although we neither cannot exclude HIV-2-transmitted drug-resistant virus nor be certain about the exact time of acquisition, we must consider the possibility that our patient acquired HIV-2 infection around 2012-2013 while adhering to a nucleoside reverse-transcriptase inhibitor backbone regimen. Until 2011, there was a sustained increase in the patient's CD4 + cell count, up to >1000/μL, which would have been unlikely had he already been infected by both HIV types. In 2014, we noted an impressive decline in the patient's CD4 + cell count, coincident with the change to a nonnucleoside reverse-transcriptase inhibitor regimen, leading to monotherapy for HIV-2 and subsequently to the accumulation of mutations conferring resistance to antiretrovirals.
In our patient, the selection of ART for dual infection had additional challenges besides HIV-2 resistance to most drug classes, including chronic kidney disease with an estimated glomerular filtration rate <70 mL/min and a high cardiovascular risk, which narrowed the safety margin for use of tenofovir disoproxil fumarate, abacavir, and darunavir.
In conclusion, HIV-2 superinfection should be considered in the presence of an unexplained and sustained decline in CD4 + cell count, even in a HIV-1-infected patient with viral load suppression. Furthermore, no data are currently available regarding emtricitabine/tenofovir disoproxil fumarate effectiveness as a pre-exposure prophylactic regimen for HIV-2, and patients should be informed accordingly. 
